سعر اوفتاتروف بلس قطرة 0.004%/0.5% 2.5 مل 2024

Travoprost 0.004% + timolol 0.5% eye drops (2.5 ml), a fixed antiglaucoma combination, Egyptian product (Mina Pharm).

• Decrease of intraocular pressure in adults with open-angle glaucoma or ocular hypertension insufficiently responsive to topical beta-blockers or prostaglandin analogues alone.Population: AdultsEMA

• Very common: ocular hyperaemia and eye irritation (>1/10). Other ocular effects include pruritus, dry eye, visual disturbances; systemic beta-blocker effects possible.International label, same formulation · EMA

• Hypersensitivity to travoprost, timolol/other beta-blockers or excipients; reactive airway disease including asthma/severe COPD; sinus bradycardia, sick sinus syndrome, 2nd/3rd degree AV block not paced, overt cardiac failure, cardiogenic shock; severe allergic rhinitis; corneal dystrophies (per EMA overview).International label, same formulation · EMA

• Systemic beta-blockade possible from ophthalmic timolol (bronchospasm, bradycardia, cardiac failure). May darken iris and thicken/darken eyelashes. Benzalkonium chloride may discolour soft contact lenses — remove lenses before instillation and wait before reinsertion. Use caution in diabetes (masks hypoglycemia) and with other beta-blockers.International label, same formulation · EMA

• Oral/ophthalmic beta-blockers / calcium channel blockers / antiarrhythmics / CYP2D6 inhibitorsModerateOral/ophthalmic beta-blockers / calcium channel blockers / antiarrhythmics / CYP2D6 inhibitors: additive systemic beta-blockade — use caution.EMA

• Prostaglandin analogues and beta-blockers: generally avoid in pregnancy unless clearly necessary; beta-blockers may cause fetal/neonatal bradycardia and hypoglycemia if used near term.International label, same formulation · EMA
• Timolol is excreted in breast milk; travoprost unknown — decide whether to discontinue nursing or the drug.International label, same formulation · EMA

• Travoprost:
• Timolol: Non-selective beta1/beta2 blocker without significant intrinsic sympathomimetic or membrane-stabilizing activity; lowers intraocular pressure (US Combigan label).